Dermorphin
Heptapeptide mu-opioid receptor agonist isolated from South American frog skin
- Class
- Opioid heptapeptide
- Half-life
- Minutes (plasma)
- Route
- Subcutaneous (SubQ)
- Cadence
- Cycled (on/off)
- Evidence
- Mixed / early human
Overview
Dermorphin is a seven-amino-acid peptide isolated in the early 1980s from the skin secretions of South American frogs (genus Phyllomedusa). It's famous in pharmacology for two reasons: it binds mu-opioid receptors with extraordinary selectivity and potency — roughly 1000× stronger than morphine in some animal tests — and it contains a D-amino acid (D-Ala) in position 2, a structural quirk almost never seen in vertebrate peptides. Indigenous Amazon tribes traditionally used frog secretions ('Kambo' or 'Sapo') for hunting stamina and mental clarity, though those preparations contained many peptides, not just dermorphin.
Only one human clinical trial has been published: a 1985 Italian RCT in 150 postoperative patients. A single 20-microgram intrathecal (spinal) injection of dermorphin provided pain relief lasting over 43 hours — significantly longer than 500 micrograms of intrathecal morphine (a dose 25 times larger). Nausea and vomiting were common (50% in open-label runs), but pretreatment with domperidone cut those rates to under 20%. The trial showed proof-of-concept efficacy but also highlighted the side-effect profile that has kept the peptide out of further clinical development. No Phase 2 or Phase 3 studies followed, and dermorphin has never been approved for medical use anywhere.
Today, dermorphin exists in two worlds: as a research tool in opioid receptor pharmacology labs, and as a banned substance on the WADA narcotics list (added in 2023 after horse-racing doping scandals). Synthetic analogs — particularly DALDA, a peripherally restricted tetrapeptide — are still studied in academic settings for neuropathic pain, but dermorphin itself has no clinical pathway forward. Material sold online as 'dermorphin' is unregulated, with no verified purity or peptide content, and carries all the risks of a potent, uncharacterised opioid.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved for human use by any regulatory authority. Never progressed past a single Phase 1-equivalent clinical trial in 1985.
- WADA banned substance (S7 narcotics, in-competition). Dermorphin and all analogs prohibited since 2023. Originally added to WADA list after horse-racing doping cases — traces found in post-race equine samples.
- Potent mu-opioid agonist — carries classic opioid risks: respiratory depression, tolerance, physical dependence, and abuse potential. The 1985 trial used microgram doses; higher doses in animals produced catalepsy and respiratory compromise.
+ 3 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching Dermorphin.
- Respiratory rate (opioids cause dose-dependent respiratory depression)
- Nausea and vomiting incidence (common, especially without antiemetic pretreatment)
- Sedation and catalepsy (reported at high doses in animal models)
- Signs of tolerance (reduced analgesic effect with repeated dosing)
- Withdrawal symptoms if dosing is abruptly stopped after chronic use
- LH and FSH (dermorphin suppresses luteinizing hormone in fertile women; effects blocked by naloxone)
Frequently asked questions
What is Dermorphin?
Heptapeptide mu-opioid receptor agonist isolated from South American frog skin. Dermorphin is a seven-amino-acid peptide isolated in the early 1980s from the skin secretions of South American frogs (genus Phyllomedusa). It's famous in pharmacology for two reasons: it binds mu-opioid receptors with extraordinary selectivity and potency — roughly 1000× stronger than morphine in some animal tests — and it contains a D-amino acid (D-Ala) in position 2, a structural quirk almost never seen in vertebrate peptides. Indigenous Amazon tribes traditionally used frog secretions ('Kambo' or 'Sapo') for hunting stamina and mental clarity, though those preparations contained many peptides, not just dermorphin.
How is Dermorphin administered?
Subcutaneous (SubQ), typically cycled (on/off).
What is the half-life of Dermorphin?
Minutes (plasma) — Rapidly degraded by peptidases; analgesic effects in tissue last far longer than plasma half-life suggests.
Is Dermorphin approved for human use?
Dermorphin is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for Dermorphin?
Evidence tier: Mixed / early human. The only published human trial (1985, 150 patients, intrathecal route) used 20 μg dermorphin vs 500 μg morphine vs placebo for postoperative pain. Dermorphin provided >43 hours of analgesia vs ~34 hours for morphine (Sato et al., cited in Dove 2018 review).
What is commonly monitored when researching Dermorphin?
Commonly tracked markers + signals: Respiratory rate (opioids cause dose-dependent respiratory depression), Nausea and vomiting incidence (common, especially without antiemetic pretreatment), Sedation and catalepsy (reported at high doses in animal models), Signs of tolerance (reduced analgesic effect with repeated dosing), Withdrawal symptoms if dosing is abruptly stopped after chronic use, LH and FSH (dermorphin suppresses luteinizing hormone in fertile women; effects blocked by naloxone).
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.